SAN FRANCISCO, March 04, 2019 /PRNewswire-PRWeb/ -- uBiome Director of Medical Affairs Dr. Sarah
The Women's Health panel will be hosted on March 12 at 12:30 pm. Experts on the panel will discuss how to effectively market "taboo" topics and why it's important for today's leaders and biggest brands to destigmatize pressing health concerns for women.
Over the years, Procter & Gamble's campaigns have tackled menstruation taboos in India, destigmatized Chinese women's choice not to marry, and celebrated new freedoms for women in Saudi Arabia. Similarly, SPARK Solutions for Growth has helped their clients market female health products related to sexual arousal, yeast infections, and overactive bladder and incontinence.
uBiome has run successful campaigns to remove the stigma around Human Papilloma Virus (HPV), sexually transmitted infections, and cervical health as part of their inclusive vaginal health check, SmartJane™.
"This is an exciting opportunity to discuss female sexuality which plays a role in promoting female empowerment," said Dr. Jessica Richman, co-founder and CEO of uBiome. "I am thrilled that Dr. Gupta will be representing uBiome alongside industry leaders to challenge the status quo."
SXSW is dedicated to helping creative people achieve their goals. Founded in 1987 in Austin, Texas, SXSW is best known for its conference and festivals that celebrate the convergence of the interactive, film, and music industries. An essential destination for global professionals, the event features sessions, showcases, screenings, exhibitions, and a variety of networking opportunities.
For more information about uBiome's community engagements, please visit https://ubiome.com/science/#community.
_____ About uBiome Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome's commercial products include SmartGut™, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; SmartFlu™, the world's first sequencing-based clinical respiratory test, which identifies more than 20 clinically relevant targets for viruses and bacteria associated with the flu and common cold; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.
Subscribe to our Free Newsletters!